Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1046 results
July 2019
-
Media ReleaseNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increasedContinuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +…
-
Media ReleaseFDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
-
Media ReleaseNovartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's preventionAfter review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11…
-
Media ReleaseSandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicineSandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
-
Media ReleaseNovartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary…
-
Key ReleaseNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolioBasel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both…
-
Media ReleaseNovartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapiesData from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
-
Media ReleaseNovartis data underpin long-term efficacy of Aimovig® where other treatments have failedData from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
June 2019
-
Media ReleaseNovartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasisNew data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]…
-
Media ReleaseNovartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosisConatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
-
Media ReleaseNew analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic diseaseFor the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of…
-
Media ReleaseNew Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacyData show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
Pagination
- ‹ Previous page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- …
- 88
- › Next page